Feb
1
New Stanozolol | Winstrol Uses
February 1, 2006 |
In a new medical study, recently published (January 2006), scientists have found new uses for stanozolol in combination with other pharmaceutical compounds.
The Department of Clinical Hematology of Xi’an Jiaotong University in China has discovered a successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and stanozolol. Here you have the conclusions of the study:
This medical team investigated the efficacy and safety of a combination regimen in 63 patients with primary refractory anemia (RA).
The daily treatment protocol comprised all-trans retinoic acid (ATRA) (30mg/m(2)), calcitriol (0.1mug/m(2)), and androgen (stanozolol 3mg/m(2), or danazol 300mg/m(2)) in three separate doses for eight consecutive weeks.
Hematologic improvement was observed in 43 (68.3%) patients. The treatment administered was generally well tolerated, with no severe regimen-related toxicity. The overall survival rates at 3 and 5 years were 68.72% and 53.18%, respectively. These results indicate that this combination regimen is an effective and well-tolerated treatment for patients with RA.
RSS feed










